Clicky

Neuren Pharmaceutica(NURPF)

Description: Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its lead product is Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion. The company is also developing NNZ-2591 that is in preclinical development for the treatment of various neurological disorders. In addition, it holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Auckland, New Zealand.


Keywords: Biopharmaceutical Organ Systems Neurological Disorders Psychiatric Diagnosis Amyotrophic Lateral Sclerosis Urological Disorders Auckland Neurodegenerative Disorders Traumatic Brain Injury Neurotrauma Fragile X Syndrome Neurological Disorder Brain Injury Concussion Brain Damage Rett Syndrome Treatment Of Rett Syndrome Severe Traumatic Brain Injury Trofinetide

Home Page: www.neurenpharma.com

697 Burke Road
Camberwell, VIC 3124
Australia
Phone: 61 3 9092 0480


Officers

Name Title
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons) CEO, MD & Director
Ms. Lauren Frazer C.A. CFO & Company Sec.
Mr. Lawrence Glass Chief Science Officer
Mr. Gerry Zhao VP of Corp. Devel.
Dr. Liza A. Squires M.D. Chief Medical Officer

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 22.2222
Trailing PE: 0
Price-to-Book MRQ: 27.9567
Price-to-Sales TTM: 203.9471
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks